Renal function largely influences Galectin-3 prognostic value in heart failure

International Journal of Cardiology

Volumn 177, Issue 1, 2014, Pages 171-177

  Zamora, Elisabet ^a,b   Lupón, Josep ^a,b   De Antonio, Marta ^a,b   Galán, Amparo ^a   Domingo, Mar ^a   Urrutia, Agustín ^a,b   Troya, Maribel ^a,b   Bayes Genis, Antoni ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarkers; Heart failure; Myocardial fibrosis; Remodeling; Renal failure

Indexed keywords

CREATININE; CYSTATIN C; GALECTIN 3; BIOLOGICAL MARKER;

AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PROGNOSIS; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; BLOOD; CAUSE OF DEATH; COMPLICATION; DISEASE COURSE; EPIDEMIOLOGY; HEART LEFT VENTRICLE FUNCTION; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPAIN; TRENDS;

AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; INCIDENCE; MALE; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SPAIN; VENTRICULAR FUNCTION, LEFT;

EID: 84909969189     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.09.011     Document Type: Article

References (33)

1. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, Böhm, and K. Dickstein ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Eur Heart J 33 14 2012 1787 1847
2. M. Jessup, W.T. Abraham, D.E. Casey, A.M. Feldman, G.S. Francis, and T.G. Ganiats 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 14 2009 1977 2016
3. A. Krzéslak, and A. Lipinska Galectin-3 as a multifunctional protein Cell Mol Biol Lett 9 2 2004 305 328
4. U.C. Sharma, S. Pokgarel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, and B. Schroen Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 19 2004 3121 3128
5. D.J. Lok, P. Van Der Meer, P.W. de la Porte, E. Lipsic, J. Van Wijngaarden, and H.L. Hillege Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 5 2010 323 328
6. R.R. Van Kimmenade, J.L. Januzzi Jr., P.T. Ellinor, U.C. Sharma, J.A. Bakker, and A.F. Low Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 6 2006 1217 1224
7. W. Tang, K. Shrestha, Z. Shao, A.G. Borowski, R.W. Troughton, and J.D. Thomas Usefulness of plasma Galectin-3 levels in systolic heart failure to predict renal insufficiency and survival Am J Cardiol 108 3 2011 385 390
8. G.M. Felker, M. Fiuzat, L.K. Shaw, R. Clare, D.J. Whellan, and L. Bettari Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ Heart Fail 5 1 2012 72 78
9. R.A. De Boer, D.J. Lok, T. Jaarsma, P. van der Meer, A.A. Voors, and H.L. Hillege Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 1 2011 60 68
10. N. Lopez-Andrés, P. Rossignol, W. Iraqi, R. Fay, J. Nuée, and S. Ghio Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial Eur J Heart Fail 14 1 2012 74 81
11. I.S. Anand, T.S. Recot, M. Kuskowski, A. Adourian, P. Muntendam, and J.N. Cohn Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT Eur J Heart Fail 15 5 2013 511 518
12. M. Lainscak, A.P. Coletta, N. Sherwi, and J.G. Cleland Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH Galectin-3 substudy, HF-ACTION Nuclear substudy, DAD-HF, and MARVEL-1 Eur J Heart Fail 12 2 2010 193 196
13. A. Bayes-Genis, M. de Antonio, J. Vila, J. Peñafiel, A. Galán, and J. Barallat Head-to-head comparison of 2 fibrosis biomarkers for long-term heart failure risk stratification. ST-2 versus Galectin-3 J Am Coll Cardiol 63 2 2014 158 166
14. J. Lupón, M. de Antonio, A. Galán, J. Vila, E. Zamora, and A. Urrutia Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment Mayo Clin Proc 88 3 2013 234 243
15. A. Bayes-Genis, M. de Antonio, A. Galán, H. Sanz, A. Urrutia, and R. Cabanes Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure Eur J Heart Fail 14 1 2012 32 38
16. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro 3rd, and H.I. Feldman CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612 [Erratum in: Ann Intern Med. 2011;155 (6): 408]
17. L.A. Inker, C.H. Schmid, H. Tighiouart, J.H. Eckfeldt, H.I. Feldman, and T. Greene Estimating glomerular filtration rate from serum creatinine and cystatin C N Engl J Med 367 1 Jul 5 2012 20 29
18. A. Bayes-Genis, E. Zamora, M. de Antonio, A. Galán, J. Vila, and A. Urrutia Soluble ST2 serum concentration and renal function in heart failure J Card Fail 19 11 2013 768 775
19. D.L. Mann Mechanisms and models in heart failure. A combinatorial approach Circulation 100 9 1999 999 1008
20. N.C. Henderson, A.C. Mackinnon, S.L. Farnworth, T. Kipari, C. Haslett, and J.P. Iredale Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am J Pathol 172 2 2008 288 298
21. D.M. Gopal, M. Kommineni, N. Ayalon, C. Koelbl, R. Ayalon, and A. Biolo Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure J Am Heart Assoc 1 5 Oct 2012 e000760
22. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 8 2010 826 832
23. A. Beiras-Fernandez, F. Weis, J. Rothkopf, I. Kaczmarek, C. Ledderose, and A. Dick Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation Ann Transplant 18 2013 643 650
24. J.J. Nativi, W.K. Kremers, T. Hasin, O. Abou Ezzeddine, S.S. Kushwaha, and B.S. Edwards Galectin-3, a biomarker of poor prognosis in heart failure remains unchanged after heart transplantation Paper presented at: AHA Congress; November 4-6, 2012; Los Angeles, CA 2012
25. Z. Dang, A. MacKinnon, L.P. Marson, and T. Sethi Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3 Transplantation 93 5 2012 477 484
26. A.P. Fernandes Bertocchi, G. Campanhole, P.H. Wang, G.M. Gonçalves, M.J. Damião, and M.A. Cenedeze A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury Transpl Int 21 10 2008 999 1007
27. D.M. Okamura, K. Pasichnyk, J.M. Lopez-Guisa, S. Collins, D.K. Hsu, and F.T. Liu Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis Am J Physiol Renal Physiol 300 1 2010 F245 F253
28. J. Lassus, V. Harjola, R. Sund, K. Siirilä-Waris, J. Melin, and K. Peuhkurinen Prognostic value of Cystatin-C in acute heart failure in relation to other markers of renal function and NT-proBNP Eur Heart J 28 15 2007 1841 1847
29. J.H. Ix, M.G. Shlipack, G.M. Chertow, S. Ali, N.B. Schiller, and M.A. Whooley Cystatin-C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study J Card Fail 12 8 2006 601 607
30. E. Zamora, J. Lupón, M. de Antonio, J. Vila, A. Galán, and P. Gastelurrutia Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification PLoS One 7 12 2012 e51234
31. E. Zamora, J. Lupon, M. de Antonio, J. Vila, J. Peñafiel, and A. Galán Long-term prognostic value for patients with chronic heart failure of estimated glomerular filtration rate calculated with the New CKD-EPI equations containing cystatin-C Clin Chem 60 3 2014 481 489
32. J.E. Ho, C. Liu, A. Lyass, P. Courchesne, M.J. Pencina, and R.S. Vasan Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and mortality. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 14 2012 1249 1256
33. C.M. O'Seaghdha, S.J. Hwang, J.E. Ho, R.S. Vasan, D. Levy, and C.S. Fox Elevated galectin-3 precedes the development of CKD J Am Soc Nephrol 24 9 2013 1470 1477